Hyderabad-based Hetero Group has stated that the Drug Controller General of India (DCGI) has issued Emergency Use Authorization (EUA) for the generic version of Tocilizumab in India for the treatment of Covid-19 in hospitalised adults. It is aimed at treating individuals who are receiving systemic corticosteroids and require supplemental oxygen, non- invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). <br />''<br />''Dr B Partha Saradhi Reddy, chairman, Hetero Group said, it demonstrates their technical capabilities and commitment to bringing important therapeutics relevant to Covid care. <br />''<br />''They will be working closely with the Government to ensure equitable distribution.<br />